Helixgate https://validator.w3.org/feed/docs/rss2.html Home Candida auris Persists in Hair Follicles, Hijacks Immune Signaling BMS picks Texas for new $2.3B manufacturing campus Sionna cystic fibrosis drug fails key trial, removing threat to Vertex BaseMap ABE Launched for Off-Target Characterization in Base Editing Therapeutic Development STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more Tenax shares nosedive as heart failure drug fails in Phase 3 STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOs Early-Life Stress Leaves Epigenetic “Scars” That Prime Stress Sensitivity BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication Denali climbs past Avlayah expectations with $3.6M in revenue Regulatory operations: The overlooked half of submission readiness From ex vivo to in vivo: Shaping the next generation of viral vector manufacturing StockWatch: Lilly Rises on Revenue Leap; Analysts High on Krystal Despite Revenue Miss Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped? Genetic Findings Provide Insights Into Leading Cause of Back Pain Trump returns to controversial vaccine policy with order questioning childhood schedule Engineered Human Interneuron Transplants Repair Respiratory Circuits in Injured Rats Third time’s the charm for Replimune as melanoma drug earns FDA greenlight STAT+: A shortage of two Sanofi medicines for Pompe disease rattles patients As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door Opinion: Fauci doesn’t have the answers on Covid’s origins. China does This week in Drug Discovery (3-7 August 2026)  Replimune to ride wave of physician support to launch advanced melanoma therapy ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit 2026 Q2 Job Market Report: Job postings keep rising as fewer companies cut employees STAT+: Pharmalittle: We’re reading about Replimune’s melanoma drug, a Medicare policy change, and more Replimune rebounds to win FDA approval of melanoma drug Is the biotech capital of the world moving? Intellia finds genetic suspect for liver safety signals with ATTR gene therapy Vistagen’s repeat-dose anxiety nasal spray can’t beat placebo in mid-stage study Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy Opinion: AI won’t enhance physician autonomy. It will further diminish it STAT+: He grew up near Boston, went to Harvard, and worked at MIT. Why did he found his startup in California? Scientists find unexpected life on Ötzi the Iceman’s 5,300-year-old body FMT Shows Promise for Peanut Allergy Tolerance in Phase I Trial Restoring pluripotency to pluripotent stem cells Tau and Alzheimer’s Disease STAT+: FDA approves Replimune melanoma drug previously rejected twice Scientists discover bacteria that lock toxic uranium into a stable form Renewed Importance of CEX in Monoclonal-Antibody Purification STAT+: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts Novel Molecular Glue Discovery Platform Unlocks Undruggable Cancer Targets BioVie shares halve on murky Parkinson’s disease readout Takeda approval ushers in new wave of sleep drugs STAT+: Up and down the ladder: The latest comings and goings